Sanuwave Health, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
~$9.3
Revenue-to-maturity cash-flow model
Base case. Range ~$7.3–$12 across our lower- and higher-growth cases (7.699999999999999%–17.7% a year).
No Buy/Hold/Sell rating is issued: only 2 valuation models apply; a rating needs 3.
Sanuwave Health, Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Revenue for the twelve months to June 2026 was $44m, up 12.7% on a year earlier, slower than the 22.5% growth a quarter earlier. Free-cash-flow margin rose to 9.6% from -0.3% a year earlier. Operating margin narrowed to 3.4% from 14.2%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 2 of our 2 financial-health checks.
Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Sanuwave Health, Inc.'s trailing-twelve-month revenue grew 12.7% year on year, with a free-cash-flow margin of 9.6%. Where it stands out: net margin of 34.7% ranks 3 of 133 health care equipment companies we cover. Where it lags: change in growth rate of -9.9pp ranks 109 of 129 health care equipment companies we cover.
Current signal Net margin expanding: TTM net margin reached 34.7%, up 137.1pp year over year.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
We value Sanuwave Health, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.1%: the 10-year Treasury yield (4.9%) plus a beta of 1.14 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | ~$9.3 ~$7.3–$12 | Primary model, counts double |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | ~$38 ~$35–$61 | Left out: out of range vs price (6.47x) |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: return on equity above 40%: buybacks or intangibles make book value too small an anchor |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | ~$5.0 ~$5.9–$25 | Included, half weight |
| Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$8.5 ~$5.0–$9.3 | 2 models |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Sanuwave Health, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2024 | 2025 | Now |
|---|---|---|---|
| Share price | $23.00 | $29.84 | $5.85 |
| Market value | $205m | $271m | $52m |
| + Net debt (− = net cash) | −$10m | $10m | $4m |
| Enterprise value | $195m | $281m | $56m |
| Multiples | |||
| Price / sales | 6.3x | 6.2x | 1.2x |
| Price / earnings | — | 22.9x | 3.4x |
| Price / free cash flow | 104.5x | 140.1x | 12.3x |
| EV / EBITDA | 42.1x | 47.5x | 21.4x |
Weak moat
How hard Sanuwave Health's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
Cash operating profit has been a median -30.4% of total assets over 8 years.
Gross margin has been a median 69.1%, moving by 14.9 percentage points (standard deviation) across 10 years.
Operating margin has been a median -187.6%; its worst year was -867.8%.
Free cash flow was positive in 1 of 9 years, at a median -143.2% of revenue.
The diluted share count fell 93.2% over five years; stock-based pay has been a median 40.1% of revenue.
AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.
Next results: November 6, 2026, after the close.
No analyst estimates are published for Sanuwave Health, Inc.: too few analysts cover it.
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Dec 2025 | $0.17 | $0.03 | −82.3% |
| Sept 2025 | $0.32 | $0.46 | +43.8% |
| Jun 2025 | −$0.09 | $0.01 | +111.1% |
Adjusted EPS as companies report it, against the average analyst estimate.
Last 12 months −79.8%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $39m | $44m | +12.7% |
| P/S multiple | 4.6x | 1.2x | −73.9% |
| Share count | 6m | 9m | −31.3% |
Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.
| Calendar year | 2025 | 2026 to date |
|---|---|---|
| Return | ||
| SNWV | +30% | −80% |
| Industry peers (median) | −16% | −13% |
| S&P 500 | +18% | +11% |
| Months that ended higher | ||
| SNWV | 50% | 36% |
| S&P 500 | 75% | 46% |
| Largest fall from a high during the year | ||
| SNWV | −41% | −87% |
| S&P 500 | −19% | −9% |
Worst fall since October 18, 2024: 91% from August 22, 2025 to September 10, 2026. Getting back needed a 1025% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 6, 2026 | −1.5% | +0.5% | −20.1% | −26.6% |
| July 13, 2026 | +2.4% | −0.4% | −45.2% | −52.9% |
| May 12, 2026 | +18.4% | +0.4% | +4.3% | −8.2% |
| April 16, 2026 | +12.8% | +1.5% | +4.6% | −7.8% |
| March 26, 2026 | −6.6% | −3.5% | −15.2% | −7.4% |
| November 7, 2025 | +29.7% | +1.7% | +24.8% | +11.6% |
| August 8, 2025 | +24.5% | +0.6% | +12.5% | +5.2% |
| July 14, 2025 | −4.3% | −0.2% | +10.1% | +19.9% |
| May 9, 2025 | −3.2% | +3.2% | +2.4% | −2.3% |
| April 8, 2025 | +3.2% | +8.8% | −2.9% | +4.5% |
| March 21, 2025 | +21.0% | +1.8% | +14.2% | −10.9% |
| January 14, 2025 | −3.9% | +2.0% | −2.5% | −7.1% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY23 Q3 | $18.9M |
| FY23 Q4 | $20.4M |
| FY24 Q1 | $22.4M |
| FY24 Q2 | $24.9M |
| FY24 Q3 | $29.3M |
| FY24 Q4 | $32.6M |
| FY25 Q1 | $36.2M |
| FY25 Q2 | $39.1M |
| FY25 Q3 | $41M |
| FY25 Q4 | $44.1M |
| FY26 Q1 | $44.3M |
| FY26 Q2 | $44M |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY23 Q3 | 21.9% |
| FY23 Q4 | 21.8% |
| FY24 Q1 | 29.4% |
| FY24 Q2 | 37.4% |
| FY24 Q3 | 55.0% |
| FY24 Q4 | 60.0% |
| FY25 Q1 | 61.5% |
| FY25 Q2 | 57.0% |
| FY25 Q3 | 39.9% |
| FY25 Q4 | 35.0% |
| FY26 Q1 | 22.5% |
| FY26 Q2 | 12.7% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY23 Q3 | -16.1% |
| FY23 Q4 | -2.6% |
| FY24 Q1 | 0.6% |
| FY24 Q2 | 3.5% |
| FY24 Q3 | 9.8% |
| FY24 Q4 | 11.8% |
| FY25 Q1 | 15.9% |
| FY25 Q2 | 14.2% |
| FY25 Q3 | 12.1% |
| FY25 Q4 | 11.2% |
| FY26 Q1 | 7.3% |
| FY26 Q2 | 3.4% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY22 Q3 | -84.9% |
| FY23 Q4 | -22.2% |
| FY24 Q1 | -14.1% |
| FY24 Q2 | -11.8% |
| FY24 Q3 | 1.2% |
| FY24 Q4 | 6.0% |
| FY25 Q1 | -1.9% |
| FY25 Q2 | -0.3% |
| FY25 Q3 | -1.9% |
| FY25 Q4 | 4.4% |
| FY26 Q1 | 9.0% |
| FY26 Q2 | 9.6% |
| Fiscal year | 2010 Dec 2010 | 2011 Dec 2011 | 2012 Dec 2012 | 2013 Dec 2013 | 2014 Dec 2014 | 2015 Dec 2015 | 2016 Dec 2016 | 2017 Dec 2017 | 2018 Dec 2018 | 2019 Dec 2019 | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | |||||||||||||||||
| Revenue | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | 13 | 17 | 20 | 33 | 44 | 44 |
| Gross profit | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 3 | 8 | 12 | 14 | 25 | 34 | 34 |
| EBITDA | −11 | −9 | −6 | −6 | −6 | −4 | −3 | −4 | −7 | −9 | −25 | −13 | −8 | 0 | 5 | 6 | 3 |
| Operating income | −12 | −9 | −6 | −6 | −6 | −4 | −3 | −4 | −7 | −9 | −25 | −14 | −9 | −1 | 4 | 5 | 2 |
| Net income | −15 | −10 | −6 | −11 | −6 | −5 | −6 | −6 | −12 | −10 | −31 | −27 | −10 | −26 | −33 | 12 | 15 |
| Diluted EPS | −$0.29 | −$0.13 | −$0.07 | −$0.10 | −$0.03 | −$0.02 | −$0.01 | −$0.01 | −$0.02 | −$0.01 | −$0.02 | −$0.01 | −$0.01 | −$3.05 | −$3.71 | $0.41 | $1.70 |
| Growth (year on year) | |||||||||||||||||
| Revenue | — | +10.2% | −4.2% | +4.0% | +5.9% | +13.9% | +42.5% | −46.3% | +150.5% | −17.4% | +165.4% | +220.7% | +28.7% | +21.8% | +60.0% | +35.0% | +12.7% |
| EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +850.0% | +27.7% | −58.9% |
| Operating income | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +28.5% | −72.9% |
| Margins | |||||||||||||||||
| Gross margin | 65.6% | 67.4% | 71.4% | 76.3% | 74.0% | 70.5% | 58.9% | 67.2% | 62.5% | 32.0% | 71.4% | 61.7% | 74.1% | 70.4% | 75.2% | 77.1% | 76.3% |
| EBITDA margin | <−999% | <−999% | −785.5% | −744.5% | −702.1% | −459.3% | −239.6% | −514.6% | −386.9% | −570.6% | −613.8% | −99.2% | −47.8% | 2.4% | 14.2% | 13.4% | 5.9% |
| Operating margin | <−999% | <−999% | −788.1% | −747.0% | −703.8% | −459.6% | −241.0% | −517.8% | −388.1% | −575.3% | −621.1% | −108.7% | −53.5% | −2.6% | 11.8% | 11.2% | 3.4% |
| Net margin | <−999% | <−999% | −832.2% | <−999% | −705.0% | −498.2% | −467.9% | −749.9% | −628.7% | −682.3% | −762.6% | −209.5% | −61.5% | −126.5% | −101.4% | 26.8% | 34.7% |
| Free-cash-flow margin | — | <−999% | −558.0% | — | −789.2% | — | −233.3% | −207.0% | −198.1% | −422.9% | −314.8% | −53.3% | — | −22.2% | 6.0% | 4.4% | 9.6% |
| Cash flow | |||||||||||||||||
| Cash from operations | −6 | −9 | −4 | −4 | −7 | −3 | −3 | −2 | −4 | −6 | −13 | −6 | −17 | −5 | 2 | 4 | 5 |
| Capital spending | — | 0 | 0 | — | 0 | — | 0 | 0 | 0 | 0 | 0 | 1 | — | 0 | 0 | 2 | 1 |
| Free cash flow | — | −9 | −4 | — | −7 | — | −3 | −2 | −4 | −6 | −13 | −7 | — | −5 | 2 | 2 | 4 |
| Stock-based pay | 3 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | — | 0 | 2 | 5 | 6 |
| Free cash flow after stock pay | — | −10 | −6 | — | −7 | — | −4 | −2 | −6 | −7 | −13 | −7 | — | −5 | 0 | −3 | −2 |
| Balance sheet | |||||||||||||||||
| Cash | 0 | 4 | 0 | 0 | 4 | 0 | 0 | 1 | 0 | 2 | 2 | 1 | 1 | 2 | 10 | 12 | 9 |
| Total debt | 0 | 0 | 5 | 2 | 0 | 0 | 5 | — | — | 1 | 32 | 26 | 22 | 7 | 0 | 22 | 13 |
| Net debt (negative = net cash) | −0 | −4 | 5 | 2 | −4 | −0 | 5 | −1 | −0 | −1 | 29 | 26 | 21 | 5 | −10 | 10 | 4 |
| Diluted shares | 52m | 78m | 84m | 113m | 193m | 252m | 430m | 555m | 598m | 814m | 1,513m | 2,073m | 2,198m | 8m | 9m | 9m | 9m |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 9 | 10 | 9 | 10 | 11 | 13 | 10 | 10 |
| Gross profit | 7 | 8 | 7 | 8 | 9 | 10 | 7 | 7 |
| EBITDA | 2 | 2 | 1 | 2 | 1 | 2 | −1 | −0 |
| Operating income | 1 | 2 | 1 | 1 | 1 | 2 | −1 | −0 |
| Net income | −21 | −13 | −6 | 1 | 10 | 8 | −1 | −1 |
| Diluted EPS | −$6.65 | −$1.12 | −$0.72 | −$0.04 | $0.39 | $0.20 | −$0.17 | −$0.08 |
| Growth (year on year) | ||||||||
| Revenue | +89.0% | +47.6% | +61.3% | +40.4% | +20.4% | +29.7% | +3.1% | −3.1% |
| EBITDA | — | +73.3% | — | −11.8% | −33.4% | +5.1% | −202.5% | −101.8% |
| Operating income | — | +93.6% | — | −12.7% | −39.1% | −0.4% | −287.0% | −119.5% |
| Net income | — | −173.0% | — | −91.1% | — | — | — | −223.8% |
| Diluted EPS | — | −109.4% | — | — | — | — | — | — |
| Margins | ||||||||
| Gross margin | 75.5% | 77.9% | 79.0% | 78.1% | 77.6% | 74.7% | 77.3% | 76.2% |
| EBITDA margin | 18.0% | 21.6% | 8.7% | 16.0% | 10.0% | 17.5% | −8.6% | −0.3% |
| Operating margin | 15.8% | 19.5% | 6.4% | 14.3% | 8.0% | 15.0% | −11.7% | −2.9% |
| Net margin | −226.1% | −128.9% | −65.6% | 5.5% | 86.0% | 57.4% | −15.0% | −7.0% |
| Free-cash-flow margin | 13.2% | 4.9% | −18.0% | −1.7% | 4.9% | 24.1% | 3.9% | 0.9% |
| Cash flow | ||||||||
| Cash from operations | 1 | 1 | −2 | 1 | 1 | 3 | 0 | 0 |
| Capital spending | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Free cash flow | 1 | 1 | −2 | −0 | 1 | 3 | 0 | 0 |
| Stock-based pay | 0 | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| Free cash flow after stock pay | 1 | −1 | −3 | −1 | −1 | 2 | −1 | −1 |
| Last 12 months unless stated | SNWV | MYO | TLSI | KRMD | CLPT | SENS | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $44m | $43m | $45m | $45m | $45m | $49m | $99m |
| Revenue growth, last 12 months | 12.7% | 6.1% | 25.2% | 22.4% | 32.5% | 90.6% | 9.2% |
| Revenue growth, 3-year average | 34.4% | 35.4% | 45.1% | 15.3% | 26.8% | 38.0% | 13.5% |
| Revenue growth, latest quarter | −3.1% | 21.3% | 1.7% | 18.2% | 36.3% | 117.8% | 10.2% |
| Gross margin | 76.3% | 68.4% | 85.8% | 62.4% | 61.4% | 54.9% | 61.2% |
| Operating margin | 3.4% | −27.1% | −67.7% | −3.7% | −70.6% | −223.2% | −8.5% |
| Operating margin, 3-year average | 7.0% | −31.6% | −122.3% | −13.3% | −66.2% | −261.7% | −17.9% |
| Net margin | 34.7% | −33.5% | −62.6% | −4.0% | −79.4% | −225.3% | −12.0% |
| Cash from operations / revenue | 11.9% | −16.4% | −50.6% | 3.1% | −103.6% | −197.6% | −1.9% |
| Free-cash-flow margin | 9.6% | −19.2% | −51.6% | 1.6% | −105.9% | −199.5% | −3.9% |
| Free-cash-flow margin, 3-year average | −0.8% | −31.0% | −119.5% | −2.7% | −58.5% | −230.3% | −7.0% |
| Stock pay / revenue | 13.4% | 6.4% | 23.6% | 6.1% | 18.4% | 23.2% | 6.1% |
| Change in share count | 78.4% | 5.9% | 73.8% | 2.5% | 6.7% | −2.8% | 4.0% |
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Revenue growth Growth | 12.7% | 9.1% | 57 of 129 |
| Change in growth rate Growth | -9.9pp | -0.6pp | 109 of 129 |
| Gross margin Profitability | 76.3% | 61.9% | 27 of 123 |
| Operating margin Profitability | 3.4% | -8.3% | 42 of 132 |
| Net margin Profitability | 34.7% | -12.0% | 3 of 133 |
| Free-cash-flow margin Cash generation | 9.6% | -3.4% | 30 of 128 |
| Stock pay as % of revenue Cash generation | 13.4% | 6.1% | 86 of 123 |
| Long-term debt as % of assets Balance sheet | 39.8% | 24.2% | 68 of 87 |
| Days sales outstanding Balance sheet | 48 days | 57 days | 35 of 118 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Consumables Parts and Accessories Revenue | $25.8M | 58.6% | ▲ 22.2% |
| System Revenue | $17.8M | 40.5% | ▲ 61.2% |
| Other Revenue | $206,000 | 0.5% | ▼ 32.7% |
| Extended Warranty | $172,000 | 0.4% | ▲ 81.1% |
| License Fees | $20,000 | 0.0% | ▼ 55.6% |
From Sanuwave Health, Inc.'s 10-K filed March 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Solas Capital Management, LLC | $6.1M | 611K | 19.1% | ▲ 112.5% |
| Awm Investment Company, Inc. | $4.5M | 455K | 14.2% | 0.0% |
| Praetorian Pr LLC | $4M | 395K | 12.3% | ▲ 12.9% |
| Vanguard Capital Management LLC | $3.5M | 353K | 11.0% | ▲ 1.1% |
| Opaleye Management Inc. | $3.1M | 306K | 9.6% | ▼ 68.8% |
| UBS Group AG | $2.6M | 257K | 8.0% | ▲ 22.1% |
| Blackrock, Inc. | $1.6M | 160K | 5.0% | ▼ 66.8% |
| Geode Capital Management, LLC | $861,394 | 86K | 2.7% | ▼ 49.9% |
| Citadel Advisors LLC | $594,730 | 59K | 1.9% | ▲ 228.6% |
| Vanguard Fiduciary Trust Co | $430,970 | 43K | 1.3% | ▼ 12.5% |
| Marshall Wace, LLP | $421,250 | 42K | 1.3% | New |
| Goldman Sachs Group Inc | $404,260 | 40K | 1.3% | ▲ 5.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Sanuwave Health, Inc.'s complete shareholder register. Values are as reported by the filers ; 2 inconsistently scaled filing rows were excluded.
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Opaleye Management Inc. 10% owner | May 1, 2026 | Sell | 500 | $16.11 | $8,055 |
| Opaleye Management Inc. 10% owner | May 1, 2026 | Sell | 10,081 | $16.11 | $162,405 |
| Opaleye Management Inc. 10% owner | April 30, 2026 | Sell | 24,000 | $16.15 | $387,600 |
| Opaleye Management Inc. 10% owner | April 30, 2026 | Sell | 1,000 | $16.15 | $16,150 |
| Opaleye Management Inc. 10% owner | April 29, 2026 | Sell | 23,360 | $17.25 | $402,960 |
| Opaleye Management Inc. 10% owner | April 29, 2026 | Sell | 1,000 | $17.25 | $17,250 |
| Opaleye Management Inc. 10% owner | April 28, 2026 | Sell | 2,500 | $18.47 | $46,175 |
| Opaleye Management Inc. 10% owner | April 28, 2026 | Sell | 43,788 | $18.47 | $808,764 |
| Opaleye Management Inc. 10% owner | April 21, 2026 | Sell | 202 | $20.50 | $4,141 |
| Opaleye Management Inc. 10% owner | April 17, 2026 | Sell | 11,267 | $20.46 | $230,523 |
| Opaleye Management Inc. 10% owner | April 17, 2026 | Sell | 5,000 | $20.46 | $102,300 |
| Manchester Management Pr, Llc 10% owner | December 12, 2025 | Sell | 6,500 | $21.04 | $136,760 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
